$INMB

INmune Bio (INMB) and Quantum Computing Inc. (QUBT) have entered a collaboration to use quantum computing and AI to identify new treatment indications and biomarkers for INmune's XPro platform. This marks QCi's first commercial customer in the pharmaceutical and biotech markets. The companies will analyze clinical and biomedical datasets to prioritize potential diseases for further study, with a focus on rare diseases.

Inmune Bio, Inc. (INMB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA R

INmune Bio (INMB) submitted regulatory packages to the EMA for Ebstrocel, its RDEB treatment, seeking orphan drug designation and pre-MAA scientific advice. The company plans EU MAA in Q1 2027, with potential market exclusivity. Ebstrocel is the first product from its CORDStrom platform.

INmune Bio (INMB) reported Q2 2026 results on an earnings call, with net loss attributable to common shareholders of $1.3 million versus a prior-year $16.5 million impairment charge. Cash and cash equivalents were $18.4 million as of June 30, 2026, expected to fund operations into Q2 2027. The company discussed Ebstracel MHRA alignment and planned late-2026 conditional authorization, plus XPro Alzheimer MRI biomarker effects.

INmune Bio (NASDAQ: INMB) said a Department of Defense-funded peer-reviewed preclinical study in 3xTg-AD mice found traumatic brain injury increased soluble TNF, TNFR1, and Aβ42 and caused learning, memory, and pain deficits. Treatment with XPro1595 prevented the injury-driven rise in amyloid pathology and improved early cognitive and pain outcomes.

INmune Bio (NASDAQ: INMB) said it will present positive Phase 2 imaging results for XPro1595 in early Alzheimer’s at AAIC. The company reported statistically significant Week 24 treatment differences in white matter myelin integrity and concordant cortical microstructure changes, supporting selective soluble TNF inhibition target engagement. Poster details include longitudinal and subgroup analyses.

INmune Bio (NASDAQ: INMB) said it filed its CORDStrom™ platform patent application into the U.S. national phase with the USPTO after a favorable PCT written opinion. The claims cover composition-of-matter and methods for Ebstrocel (pobistrocel) for epidermolysis bullosa and related engineered MSC modalities, with potential protection into at least 2045 if granted.

Inmune Bio, Inc. (INMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ea029662401ex10-1.htm FORM OF INDUCEMENT LETTER Exhibit 10.1 INMUE BIO INC. 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 June 29, 2026 To the Holder of April 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase

INmune Bio Inc. (NASDAQ: INMB) said the UK MHRA approved the Pediatric Investigation Plan for Ebstrocel™ for recessive dystrophic epidermolysis bullosa (RDEB). The company said this is the first step toward a UK marketing authorization application, aligned with an MAA in 2026 and a US accelerated approval filing in early 2027.

INmune Bio said the UK MHRA accepted written minutes from a May 12 pre-MAA Scientific Advice meeting for CORDStrom™/Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB). The agency aligned on CMC, non-clinical and clinical evidence, and noted MissionEB Phase 2 showed clinically meaningful symptomatic benefit (pain, itch), supporting chronic/intermittent supportive therapy positioning. The company plans a 2026 UK conditional MAA, with EU and US filings later.